Surgery Partners, Inc.
SGRY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 4.02 | 0.99 | 0.84 |
| FCF Yield | 7.85% | 5.10% | 3.05% | 0.76% |
| EV / EBITDA | 12.17 | 15.43 | 11.32 | 16.89 |
| Quality | ||||
| ROIC | 0.40% | 5.11% | 4.33% | 4.63% |
| Gross Margin | 23.94% | 23.60% | 22.64% | 22.08% |
| Cash Conversion Ratio | 24.01 | 2.17 | 1.83 | 1.23 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.04% | 7.23% | 10.93% | 6.71% |
| Free Cash Flow Growth | 2.29% | 162.15% | 165.08% | -85.54% |
| Safety | ||||
| Net Debt / EBITDA | 6.85 | 6.42 | 5.75 | 7.24 |
| Interest Coverage | 1.73 | 1.70 | 1.47 | 1.37 |
| Efficiency | ||||
| Inventory Turnover | 26.80 | 27.87 | 27.51 | 28.37 |
| Cash Conversion Cycle | 49.33 | 49.22 | 50.69 | 57.14 |